MedTrace Logo

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

NCT01483586 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2014-04-14

No results posted yet for this study

Summary

This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.

Conditions

Interventions

DRUG

kanglaite gelcap

3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule

DRUG

Kanglaite gelcap

6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT

Sponsors & Collaborators

  • KangLaiTe USA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01483586 on ClinicalTrials.gov